NABIXIMOLS

Possibly Marketed Outside US

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24430917https://www.ncbi.nlm.nih.gov/pubmed/17630726
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23621668 | https://www.ncbi.nlm.nih.gov/pubmed/22954177 | https://www.ncbi.nlm.nih.gov/pubmed/24525548 | https://www.ncbi.nlm.nih.gov/pubmed/25777582 | https://www.ncbi.nlm.nih.gov/pubmed/23401746

CB-13 is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. CB-13 displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17630726	Agonist 2678	6.1 nM [EC50]
Cannabinoid CB2 receptor 71 Target ID: CHEMBL253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17630726	Agonist 2678	27.9 nM [EC50]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17630726	Inhibitor 8297	80800.0 nM [IC50]
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22284817	Agonist 2678	10.0 nM [Ki]
Cannabinoid CB2 receptor 71 Target ID: CHEMBL253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000707	Agonist 2678	42.0 nM [Ki]
Vanilloid receptor 53 Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25029033	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17630726	Primary	Phase I 428	Unknown Approved Use Unknown
Neuropathic pain 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23621668	Primary	Approved 8429	Sativex Approved Use Unknown
Spasticity 11 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22954177	Primary	Approved 8429	Sativex Approved Use Unknown
Cannabinoid dependence 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25777582	Primary	Phase III 656	Sativex Approved Use Unknown
Tourette's syndrome 20 Sources: https://clinicaltrials.gov/ct2/show/NCT03087201	Primary	Phase III 656	Sativex Approved Use Unknown

PubMed

Title	Date	PubMed
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.	2007 Aug 9	17630726

Patents

Sample Use Guides

In Vivo Use Guide

2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Mixture Created by `admin` on `Sat Dec 16 00:22:25 GMT 2023` Edited by `admin` on `Sat Dec 16 00:22:25 GMT 2023`
Record UNII	K4H93P747O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NABIXIMOLS

Official Name

English

SAB 378

Code

English

GW 1000

Code

English

NABIXIMOLS [USAN]

Common Name

English

GW-1000

Code

English

GW 1000-02

Code

English

SATIVEX

Brand Name

English

TETRANABINEX

Brand Name

English

NABIDIOLEX

Brand Name

English

SAB-378

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29631